FOR IMMEDIATE RELEASE
CONTACT:
Susan Lorigan
Investor Relations
(510-623-9001)
SUNRISE TECHNOLOGIES ADDS TO BOARD OF DIRECTORS AND CHANGES CORPORATE SECRETARY/COUNSEL
Fremont, California, October 1, 1997, - Sunrise Technologies International, Inc. (OTC:SNRS)-- adds to the Board of Directors and changes Corporate Secretary/Counsel.
Today, Sunrise Technologies Int'l, Inc., named Michael S. McFarland, M.D., to its Board of Directors. Dr. McFarland is a cataract and refractive surgeon in Arkansas.
"Members of my management team and I have known Dr. McFarland well for over ten years, and he has always displayed a great intellectual curiosity for new technologies. Evidence to that is the fact that he was the fourth recipient of the Innovators Award, given by the Irish American Ophthalmological Society for his pioneering work in the area of sutureless cataract surgery. Previous recipients of this prestigious award were Svyatoslav Fyodorov of Russia, Thomas Neuhann, M.D., of West Germany, and Charles D. Kelman, M.D., of the United States," according to C. Russell Trenary III, President and CEO. "It is also worth noting Dr. McFarland was chosen by his peers as one of the "Best Doctors in America," in a survey conducted by an independent company. Only 2% of our nation's practicing doctors were selected," Mr. Trenary explained.
Additionally, Dr. McFarland has one of the largest cataract and refractive practices in the country. It is important for Sunrise to maintain active dialogue with successful practitioners around the country to ensure we meet our customers' needs. Dr. McFarland's advice, based on his own experiences and from his frequent communication with other successful surgeons will benefit us tremendously," continued Mr. Trenary.
Dr. McFarland, in accepting nomination to Sunrise's Board of Directors stated, "I am excited about participating as a member of the Sunrise Board because I believe in the technology and their management team. The Sunrise method for treating hyperopia could be a godsend for patients with this condition. I think this is the most exciting innovation in ophthalmology in a long time and will have a huge impact on refractive surgery around the world."
In a related announcement, Sunrise introduced that they have retained Eric M. Fogel, Esq., of Holleb and Coff, located in Chicago, IL, to act as Secretary of the Corporation, and Corporate Counsel.
"Eric brings to Sunrise a rich background in the area of corporate finance, securities, and lending as well as general corporate representation. He graduated summa cum laude, Phi Beta Kappa from Pomona College and his M.A., JD, and MBA are from the University of Michigan. His commitment, energy level, and creativity are already serving Sunrise very, very well," says Trenary.
"It is not common for me to become involved in entities beyond the number with whom I am currently working," stated Mr. Fogel. "But the new team at Sunrise, with their experience, spirit, and business opportunity, provide an exciting challenge that I could not pass up," explained Eric.
Finishing, Mr. Trenary stated, "It is important for us to strengthen the arena of corporate governance, and the addition of Dr. McFarland and Mr. Fogel go a long way toward creating excellence in this area."
Founded in 1987, Sunrise Technologies International, Inc., produces and markets high technology products revolutionizing treatment methods in eye care. The company develops Holmium laser-based systems which utilize a patented process for shrinking collagen developed by Dr. Bruce Sand (the "Sand Process") in correcting ophthalmic conditions. Its CorneaSparing LTK(tm) System* is a non-contact simultaneous application for correction of hyperopia (farsightedness), presbyopia (loss of near focus due to natural aging), and overcorrection resulting from PRK and LASIK treatments for myopia. The system is currently in use in Europe and the Americas, and is in FDA clinical trials in the United States.
Except for historical information, this news release contains certain forward-looking statements that involve risk and uncertainties which may cause actual results to differ materially from the statements made, including market potential, regulatory clearances, business growth, and other risks listed from time to time in Sunrise Technologies' U.S. Securities and Exchange Commission (SEC) filings. These forward-looking statements represent Sunrise Technologies' judgment, as of the date of this release, and the company disclaims any intent or obligation to update these forward-looking statements.
Internet users can access Sunrise's World Wide Web site at sunrise-tech.com.
*Caution--Investigational Device: Federal law restricts this device to investigational use in the U.S.
End of Press Release
Disclaimer from Nanny: I do not have a scanner so I typed this press release here. Any misspellings are mine!
Enjoy!!
Regards,
Nanny |
